Hemostemix Inc
Research Hemostemix Inc (HEM) on Bullrun: market cap CAD 13.32M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHEM
- ExchangeV
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCAD
- Market capCAD 13.32M
- Financial periodQ1 2026
- RevenueCAD 0
- Net income-CAD 789.98K
- Free cash flow-CAD 814.50K
Valuation Snapshot
latest market cap is CAD 13.32M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 4.71M | -CAD 4.53M | n/a | n/a | CAD 682.12K | CAD 3.60M | -CAD 4.97M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-15 | CAD 13.32M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CAD.
About Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hemostemix Inc's market cap?
Hemostemix Inc's market capitalization is CAD 13.32M.
What does Hemostemix Inc do?
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which completed Phase II clinical trial for the treatment of peripheral arterial disease, chronic limb threatening ischemia, cardiovascular ischemia and angina, and vascular dementia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.